Impact of Resveratrol on Brain Function and Structure
Ключові слова
Анотація
Опис
Cell and animal studies postulated various beneficial effects of resveratrol, ranging from a reduction of inflammatory processes and the treatment of cancer to the prevention of cardiovascular diseases and stroke. With regard to cognitive decline, rodent models for Alzheimer's disease (AD) showed improved learning and decelerated hippocampal neurodegeneration after intake of resveratrol.
Animal and first human studies provided evidence that resveratrol might serve as an easy, cost-effective option to develop novel prevention and treatment strategies against age-associated cognitive decline. To test this hypothesis, the researchers study general brain structure and function on healthy older individuals (> 60years old).
Дати
| Востаннє перевірено: | 01/31/2017 |
| Перший поданий: | 11/05/2015 |
| Орієнтовна реєстрація подана: | 11/30/2015 |
| Опубліковано вперше: | 12/02/2015 |
| Останнє оновлення надіслано: | 02/05/2017 |
| Останнє оновлення опубліковано: | 02/07/2017 |
| Фактична дата початку навчання: | 03/31/2016 |
| Розрахункова дата первинного завершення: | 12/31/2016 |
| Розрахункова дата завершення дослідження: | 12/31/2016 |
Стан або захворювання
Втручання / лікування
Dietary Supplement: resveratrol supplementation
Dietary Supplement: placebo supplementation
Фаза
Групи рук
| Рука | Втручання / лікування |
|---|---|
| Experimental: resveratrol supplementation Dietary Supplement: Resveratrol | Dietary Supplement: resveratrol supplementation 6 months of resveratrol supplementation |
| Placebo Comparator: placebo supplementation Dietary Supplement: Placebo | Dietary Supplement: placebo supplementation 6 months of placebo intake |
Критерії прийнятності
| Вік, придатний для навчання | 60 Years До 60 Years |
| Стать, яка підходить для вивчення | All |
| Приймає здорових добровольців | Так |
| Критерії | Inclusion Criteria: - subjects who are healthy or with subjective memory complaints - older than 60 years old - normal to overweight participants (BMI: 22-40 kg/sqm) Exclusion Criteria: - dementia - Psychiatric diseases - severe untreated internal diseases - diabetes - younger than 60 years - BMI < 22 or >40 |
Результат
Заходи первинного результату
1. Change from baseline Verbal Learning Task Scores at 6 months [Baseline (timepoint 0), after 6 months (timepoint 6 months)]
Заходи вторинного результату
1. Change from baseline Verbal Learning Task Scores at 12 months [after 12 months (timepoint 12 months)]
2. Mini Mental State Examination [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
3. Structural changes on the brain MRI images [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
4. Functional changes on the brain MRI images [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
5. Plasma biomarkers [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
